Abstract
Bone mineral density (BMD) of the lumber vertebrae and factors related to bone metabolism were determined in patients with chronic viral hepatitis and patients with liver cirrhosis to clarify correlations between hepatic dysfunction, considered to be one of the causes of hepatic osteodystrophy, and decrease in bone mass. BMD of the second to fourth lumbar vertebrae was determined with a Lunar (Madison, WI, USA) DPX, a dual-energy X-ray absorptiometry diagnostic system. BMD was significantly lowest in patients with liver cirrhosis, followed by patients with chronic hepatitis, and healthy subjects, in this order. There was a significantly positive but weak correlation between albumin and BMD. Levels of 25(OH)D and 1,25(OH)2D were significantly lower in patients with liver cirrhosis than in those with chronic hepatitis. BMD and vitamin D were decreased in all patients whose cholinesterase (ChE) was below 0.3ΔpH. Urinary pyridinoline(Upyr) was significantly higher in the patients with liver cirrhosis, in whom bone mass was decreased, than in the patients with chronic hepatitis, whereas serum osteocalcin levels were distributed in the upper normal range in patients with chronic hepatitis and those with liver cirrhosis. There was a positive correlation between 25(OH)D and serum osteocalcin levels in patients with liver cirrhosis. These results indicate that osteogenesis is decreased and suggest that the decrease in BMD which occurs in viral liver cirrhosis, probably related to decreased, bone formation and slight promotion of bone resorption, reflects deranged hepatic function. This is the first report of Upyr and urinary deoxypyridinoline (UDpyr) determination in patients with liver cirrhosis and patients with chronic hepatitis. The negative correlation of Upyr and UDpyr with ChE is a novel finding.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Heaf JG. Hepatic osteodystrophy. Scand J Gastroenterol 1985; 20:1035–1040.
Atkinson M, Nordin BEC, Sherlock S. Malabsorption and bone disease in prolonged obstructive jaundice. QJ Med 1956;25:299–312.
Kehayoglou AK, Holdsworth CD, Agnew JE, et al. Bone disease and calcium absorption in primary biliary cirrhosis. Lancet 1968;I:715–719.
Levin ME, Boissequ VC, Avioli LV. Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes. New Engl J Med 1976;294:241–245.
Masuda S, Okano T, Kobayashi T, et al. A method for the simultaneous edtermination of vitamin D2,D3 and their metabolites in plasma and its applicantion to plasma samples obtained from normal subjects and patients. Food Chem 1992;45:215–225.
Long RG, Meinhard E, Skinner RK, et al. Clincal, biochemical and histological studies of osteomalacia, osteoporosis and parathyroid function in chronic liver disease. Gut 1978;19:85–90.
Posner DB, Russell RM, Absood S, et al. Effective 25-hydroxylation of vitamin D2 in alcoholic cirrhosis, Gastroenterology 1978;74:866–870.
Dibble JB, Sheridan P, Hampshire R, et al. Osteomalacia, vitamin D deficiency and cholestasis in chronic liver disease. QJ Med 1983;52:89–103.
Albright F, Smith PH, Richardson AM. Postmenopausal osteoporosis—its clinical features. JAMA 1941;116:2465–2474
Adinoff AD, Hollister JR, Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983;309:265–268.
Diamond T, Stiel D, Lunzer M, et al. Osteoporsis and skeletal fractures in chronic liver disease. Gut 1990;31:82–87.
Kalbfleisch JM, Lindeman RD, Ginn HE, et al. Effects of ethanol administration on urinary excretion of magnesium and other electrolytes in alcoholic and normal subjects. J Clin Invest 1963; 42:1471–1475.
Kanda T, Otsuki M, Hayashi Y, et al. Clinical and biochemical studies of osteopenia in liver cirrhosis. Nippon Shokakibyo Gakkai Zasshi (Jpn J Gastroenterol) 1988;85:1088–1094.
Kanda T, Shimizu Y, Nakano A, et al. Secondary osteopenia in chronic liver disease. Acta Hepatol Jap 1995;36:67–75.
Namihisa T, Watanabe J, Aoyagi T, et al. Clincal effect of active vitamin D3 on hepatic osteodystrophy by multi-center open study (in Japanese). KAN-TAN-SUI 1990;20:549–555.
Bonkovsky HL, Hawkins M, Steinberg K. Prevalence and prediction of osteopenia in chronic liver disease. Hepatology 1990: 12:273–280.
Pietschmann P, Resch H, Muller Ch, et al. Decreased serum osteocalcin levels in patients with liver cirrhosis. Bone Miner 1990;8:103–108.
Fujiyama S, Iida S, Sagara K, et al. Serum calcitonin levels in patients with various liver diseases. Dig Med 1987;6:203–210.
Uebelhart D, Gineyts E, Chapuy M-C, et al. Urinary excretion of pyridinium crosslinks: A new marker of bone resorption in metabolic bone disease. Bone Miner 1990;8:87–96.
Delmas PD, Schlemmer A, Gincyts E, et al. Urinary excretion of crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res 1991;6:639–644.
Diamond TH, Stiel D, Lunzer M, et al. Hepatic osteodystrophy. Gastroenterology 1989;96:213–221.
Imawari M, Akanuma Y, Itakura H, et al. The effects of disease of the liver on serum 25-hydroxyvitamin D and on the serum binding protein for vitamin D and its metabolites. J Lab Clin Med 1979; 93:171–180.
Imawari M. Vitamin D (in Japanese). Kantansui (KAN-TAN-SUI) 1989;18:567–570.
Conte N, Cecchettin M, Manente P, et al. Calcitonin in hepatoma and cirrhosis. Acta Endocrinol 1984;106:109–111.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tsuneoka, K., Tameda, Y., Takase, K. et al. Osteodystrophy in patients with chronic hepatitis and liver cirrhosis. J Gastroenterol 31, 669–678 (1996). https://doi.org/10.1007/BF02347615
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02347615